Thursday, October 31, 2024
9:23 AM EST – BioVaxys Technology Corp : Announces studies showing that its novel immune educating delivery platform, DPX™, recruits and activates unique subsets of antigen presenting cells to drive immunogenicity of antigens, and exhibits superior immune activation compared to aqueous and emulsion-based antigen delivery systems. BioVaxys Technology Corp
(C.BIOV) shares were unchanged at 0.07.
Stocks in Play: BioVaxys Technology Corp, Thu, 31 Oct 2024 09:27:06 EST